AXA China Region Insurance Company (Bermuda), together with AXA International Reinsurance (Shanghai) Company, has signed a Memorandum of Understanding (MoU) with China Biotech Services.
The collaboration aims to explore innovative cancer treatment technologies, including Boron Neutron Capture Therapy (BNCT) and related services, with the goal of providing customers with a broader range of diversified treatment options. BNCT is a targeted radiotherapy that involves administering a boron-containing drug as a targeting agent.
BNCT offers greater precision than traditional radiotherapy, effectively targeting cancer cells without damaging nearby normal cells, and is particularly suitable for treating malignant tumours resistant to traditional radiotherapy or those that have recurred, such as malignant gliomas (brain tumours) and recurrent head and neck cancers.
“AXA remains deeply committed to a customer-first philosophy, offering comprehensive and high-quality medical protection tailored to individual needs,” said AXA Hong Kong and Macau chief life and health insurance officer Janet Lee.
“We continuously track healthcare trends and integrate cutting-edge medical solutions into our insurance plans to ensure our services remain relevant and impactful.”
Ms Lee also said, “We are delighted to collaborate with China Biotech Services to jointly explore innovative medical technologies and pharmaceuticals, further enhancing our insurance offerings and deliver exceptional health protection and a wide range of care options to customers in need.”